ClinicalTrials.gg
Not yet recruitingNCT07933224Updated Nov 12, 2026

A Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HS-10382 Tablets in Healthy Participants

A Phase 1 interventional study of HS-10382 in Healthy Volunteers, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The high-fat meal food effect part adopts a single-center, randomized, open-label, two-sequence, two-period, two-way crossover dosing design. Based on the results of the high-fat meal food effect trial, the sponsor and the principal investigator will comprehensively analyze and determine whether a low-fat meal food effect trial needs to be conducted.

Read the detailed description

This is a single-center, randomized, open-label, two-sequence, two-period, two-way crossover dosing design. A total of 16 participants are planned to be enrolled in each part. Eligible participants will be randomly assigned at a 1:1 ratio into two dosing sequence groups: Group 1 (A-B) and Group 2 (B-A) (A = fasting administration, B = postprandial administration), with 8 participants in each group. Enrolled participants will be admitted to the Phase I clinical trial unit on Day -1 and fast for at least 10 h before dosing. On the morning of the dosing day, a blank blood sample will be collected, after which participants will receive a single oral dose of HS-10382 tablets 160 mg under fasting conditions or after a high-fat/ low-fat meal according to their assigned dosing sequence group. Crossover dosing will be performed after a 7-day interval. The drug will be administered with approximately 240 mL of water. Water intake will be prohibited within 1 h before and after dosing (except for the water used for dosing and beverages included in the meal), and food intake will be prohibited within 4 h after dosing.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Phase I
  • Food effect
  • HS-10382
  • Healthy volunteers
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed before the trial, with full understanding of the trial content, procedures, and possible adverse reactions, and self-reported ability to complete the study according to the study requirements;
  2. Adult males and females (age ≥18 years, calculated as of the day of signing the informed consent form);
  3. Participant (BMI) = weight (kg)/height² (m²), with BMI within the range of 19.0-26.0 kg/m² (inclusive). Male participants must weigh ≥50 kg, and female participants must weigh ≥45 kg;
  4. Agree to use highly effective from the time of signing the informed consent form until 6 months after the last dose of HS-10382, and have no plans for conception or sperm/egg donation during this period.

Exclusion criteria

Exclusion Criteria:

  1. Have abnormalities, as judged by the investigator, in physical examination, vital signs, 12-lead , clinical laboratory tests (complete blood count, blood biochemistry, urinalysis, coagulation function), abdominal ultrasound, etc. during the screening period;
  2. Have a history of , , , or syphilis, and/or any one or more clinically significant abnormalities in the four infectious disease screening tests;
  3. Have a history of, or current, severe diseases of the nervous system, psychiatric system, digestive system, circulatory system, respiratory system, urinary system, etc., or have new-onset disease before use of the drug, which the investigator considers unsuitable for participation in this study;
  4. Have gastrointestinal dysfunction, dysphagia, or a history of surgery affecting drug absorption, distribution, metabolism, or excretion, which the investigator judges unsuitable for enrollment;
  5. Have susceptibility to allergic reactions or an allergic constitution (e.g., allergy to pollen, or to two or more drugs/foods), or have a known allergy to the investigational drug or any of its components;
  6. Have participated in any other clinical trial and used investigational drugs or devices within 3 months before the first dose;
  7. Have donated blood and/or lost more than 200 mL of blood (excluding menstrual blood loss in females) within 3 months before the first dose, and/or received a blood transfusion or blood products, or have plans to donate blood during the study;
  8. Have had excessive intake of tea, coffee, and/or caffeine-containing beverages within 3 months before screening (more than 8 cups per day on average, 1 cup = 200 mL), or be unable to stop intake of tea, coffee, and/or caffeine-containing beverages during the study;
  9. Have ingested grapefruit or grapefruit products within 48 h before the first dose, or be unable to stop intake of grapefruit or grapefruit products during the study;
  10. Have had regular alcohol consumption within 3 months before screening (i.e., more than 14 units of alcohol per week; 1 unit = 14 g alcohol, equivalent to 360 mL beer, 45 mL liquor with 40% alcohol, or 150 mL wine; equivalent to 10 bottles of beer, 1 jin of baijiu, or 3 bottles of red wine per week), or have a positive blood alcohol test, or be unable to stop consumption of alcoholic products during the study;
  11. Have smoked more than 5 cigarettes per day on average within 3 months before screening, or be unable to stop use of any tobacco products during the study;
  12. Have a history of drug abuse or drug dependence, or have used illicit drugs within 5 years before screening, or have a positive urine drug abuse screening result;
  13. Have used any drug that may affect P-gp, BCRP, and/or CYP 2B6 or 3A enzyme activity within 30 days or 5 half-lives of the drug (whichever is longer) before the first dose;
  14. Have used any prescription drug, over-the-counter drug, herbal medicine, or health product (except topical preparations with local action) within 14 days before the first dose;
  15. Be unable to tolerate venipuncture/indwelling needle blood collection, or have a history of needle or blood phobia;
  16. Be breastfeeding within 1 month before screening or during the study, or have a positive pregnancy test result during the screening period (for female participants of );
  17. Be likely unable to complete this study for other reasons, or be judged unsuitable for participation by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    HS-10382 (fasting, fed)

    On the morning of the dosing day, a blank blood sample will be collected, after which participants will receive a single oral dose of HS-10382 tablets 160 mg under fasting conditions or after a high-fat/ low-fat meal according to their assigned dosing sequence group.

    Drug: HS-10382

  • Experimental
    HS-10382 (fed, fasting)

    On the morning of the dosing day, a blank blood sample will be collected, after which participants will receive a single oral dose of HS-10382 tablets 160 mg under fasting conditions or after a high-fat/ low-fat meal according to their assigned dosing sequence group.

    Drug: HS-10382

Interventions

  • Drug: HS-10382 Comes in 40 mg tablets and taken orally

06

What researchers measure

Primary outcomes

  1. Evaluation of PK parameters of HS-10382: Cmax

    To evaluate the Cmax of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  2. Evaluation of PK parameters of HS-10382: AUC0-t

    To evaluate the AUC0-t of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  3. Evaluation of PK parameters of HS-10382: AUC0-∞

    To evaluate the AUC0-∞ of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

Secondary outcomes

  1. Evaluation of PK parameters of HS-10382: Tmax

    To evaluate the Tmax of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  2. Evaluation of PK parameters of HS-10382: tlag

    To evaluate the tlag of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  3. Evaluation of PK parameters of HS-10382: t1/2z

    To evaluate the t1/2z of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  4. Evaluation of PK parameters of HS-10382: λz

    To evaluate the λz of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  5. Evaluation of PK parameters of HS-10382: CL/F

    To evaluate the CL/F of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  6. Evaluation of PK parameters of HS-10382: Vz/F

    To evaluate the Vz/F of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  7. Evaluation of PK parameters of HS-10382: MRT

    To evaluate the MRT of HS-10382 following fasting or fed administration

    Time frame: 96 hours after administration of HS-10382

  8. Adverse events

    To evaluate the vital signs of HS-10382 following fasting or fed administration

    Time frame: Up to end of the study, approximately 1 month.

  9. vital signs (blood pressure)

    To evaluate the vital signs(blood pressure) of HS-10382 following fasting or fed administration

    Time frame: Up to end of the study, approximately 1 month

  10. vital signs (Pulse)

    To evaluate the vital signs(Pulse) of HS-10382 following fasting or fed administration

    Time frame: Up to end of the study, approximately 1 month

  11. vital signs (body temperature)

    To evaluate the vital signs(body temperature) of HS-10382 following fasting or fed administration

    Time frame: Up to end of the study, approximately 1 month

  12. clinical laboratory tests(complete blood count (CBC), urinalysis, blood chemistry, coagulation tests)

    To evaluate the clinical laboratory tests (complete blood count (CBC), urinalysis, blood chemistry, coagulation tests) of HS-10382 following fasting or fed administration.

    Time frame: Up to end of the study, approximately 1 month

  13. 12-lead electrocardiogram (include heart rate, PR, RR, QRS duration and QTcF)

    To evaluate the 12-lead electrocardiogram(include heart rate, PR, RR, QRS duration and QTcF) of HS-10382 following fasting or fed administration.

    Time frame: Up to end of the study, approximately 1 month

  14. physical examination of HS-10382 following fasting or fed administration

    To evaluate the abnormal of the physical examination (general inspection, head and neck, lymph nodes, chest, abdomen, spine and extremities, and neurological examination) of HS-10382 following fasting or fed administration.

    Time frame: Up to end of the study, approximately 1 month

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 12, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07933224
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Wei Hu, Ph.D
Contact
huwei@ahmu.edu.com
+86 13856086475
Renpeng Zhou, Ph.D
Contact
zhourenpeng@ahmu.edu.cn
+86 15956933545

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Embibatinib

Start the discussion